FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:839-847 March 30, 1995 Number 13 Next

Abstract PDF Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Turcot's syndrome is characterized clinically by the concurrence of a primary brain tumor and multiple colorectal adenomas. We attempted to define the syndrome at the molecular level.

Methods Fourteen families with Turcot's syndrome identified in two registries and the family originally described by Turcot and colleagues were studied. Germ-line mutations in the adenomatous polyposis coli (APC) gene characteristic of familial adenomatous polyposis were evaluated, as well as DNA replication errors and germ-line mutations in nucleotide mismatch-repair genes characteristic of hereditary nonpolyposis colorectal cancer. In addition, a formal risk analysis for brain tumors in familial adenomatous polyposis was performed with a registry data base.

Results Genetic abnormalities were identified in 13 of the 14 registry families. Germ-line APC mutations were detected in 10. The predominant brain tumor in these 10 families was medulloblastoma (11 of 14 patients, or 79 percent), and the relative risk of cerebellar medulloblastoma in patients with familial adenomatous polyposis was 92 times that in the general population (95 percent confidence interval, 29 to 269; P<0.001). In contrast, the type of brain tumor in the other four families was glioblastoma multiforme. The glioblastomas and colorectal tumors in three of these families and in the original family studied by Turcot had replication errors characteristic of hereditary nonpolyposis colorectal cancer. In addition, germ-line mutations in the mismatch-repair gene hMLH1 or hPMS2 were found in two families.

Conclusions The association between brain tumors and multiple colorectal adenomas can result from two distinct types of germ-line defects: mutation of the APC gene or mutation of a mismatch-repair gene. Molecular diagnosis may contribute to the appropriate care of affected patients.

Two major inherited syndromes with colorectal neoplasia can now be characterized at the molecular genetic level: familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (or Lynch syndrome). In familial adenomatous polyposis there is a germ-line alteration of the adenomatous polyposis coli (APC) gene^{10,11,12,13,14,15,16,17,18}; mutations of the gene can be detected in about 80 percent of families with familial adenomatous polyposis.¹⁷ The condition has an autosomal dominant inheritance, but up to one third of cases appear without a positive family history.¹⁹ Typically, hundreds to thousands of colorectal adenomas develop in familial adenomatous polyposis, although in some families only small numbers occur.²⁰ A variety of benign and malignant extracolonic manifestations have been reported in this condition.^{7,21,22,23,24,25,26,27,28,29,30}

In hereditary nonpolyposis colorectal cancer, a germ-line mutation occurs in one of a group of genes involved in DNA nucleotide mismatch repair, including hMSH2 (human mutS homologue 2),^31,32,33,34 hMLH1 (human mutL homologue 1),^35,36,37 and hPMS1 and hPMS2 (human postmeiotic segregation 1 and 2).³⁸ The DNA in cancers of patients with hereditary nonpolyposis colorectal cancer has characteristic errors of replication, also termed microsatellite instability, that are due to the uncorrected mispairing of nucleotides and resultant misalignment of DNA strands.^39,40,41,42 This condition, like familial adenomatous polyposis, is autosomal dominant, but it is difficult to recognize clinically because the colorectal and extracolonic cancers are not distinctive.^43,44

Previous genetic analysis of a few patients with Turcot's syndrome has not revealed the molecular pathogenesis.^{45,46,47,48,49,50,51,52,53} We therefore evaluated 14 families and one of the patients originally described by Turcot and colleagues¹ for genetic evidence of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. We also carried out a formal risk analysis for brain tumors in a registry of patients with familial adenomatous polyposis. Our findings have implications for the care of patients as well as the classification of the diseases.

Methods

Study Patients

We studied 14 families that each included a patient with a primary brain tumor and either multiple colorectal adenomas or a family history of adenomatous polyposis (Figure 1 and Table 1). (When two members of the same family had brain tumors, they were designated A and B, as shown in Figure 1 and Table 1.) A 15th family was identified, but specimens were not available for study. The families were identified through 1993 from the Bowel Tumor Working Group Registry at Johns Hopkins Hospital in Baltimore and the Familial Gastrointestinal Cancer Registry at Mount Sinai Hospital in Toronto. Adenomatous polyposis was defined by the presence of more than 100 colorectal adenomas.⁵⁴ Hereditary nonpolyposis colorectal cancer was defined according to the criteria of the International Collaborative Group.⁵⁵

View larger version (17K): [in this window] [in a new window]   Figure 1. Association between the Change in Body Weight after the Age of 25 and the Risk of Hip Fracture. The rate of hip fracture is adjusted for age. The T bars denote the upper 95 percent confidence limits.

 

View this table: [in this window] [in a new window]   Table 1. Clinical Characteristics of the Study Patients with Turcot's Syndrome.

 
The Hopkins registry contained 368 families with adenomatous polyposis, 102 with hereditary nonpolyposis colorectal cancer, and 517 with familial aggregation of colorectal adenomas and carcinomas. Eleven families with Turcot's syndrome were identified (Families 1 through 8, 11, 13, and 14). Peripheral-blood leukocytes were obtained for the analysis of mutations by venipuncture from the family member with a brain tumor or from another affected member after informed consent was given. Six of the patients (Patients 1A, 3B, 4A, 4B, 8, and 11) have been described previously.^53,56,57 The Toronto registry included 230 families, among which 4 with Turcot's syndrome were identified. A sample of peripheral blood was obtained from three (Families 9, 10, and 12), but not from Family 15. Two families (Families 9 and 12) have been described previously.^58,59

The Family Described by Turcot et Al.

The two siblings described by Turcot et al. were identified in the pathology records of l'Hôtel-Dieu de Québec and l'Hôpital de l'Enfant-Jésus in Quebec from the dates reported in the original publication.¹ A review of the histopathologic sections confirmed the published findings, except for the presence at autopsy in Subject 2 of a 3-cm hepatic adenoma not described in the case report. The photographs of the colorectal specimens¹ were subjected to image processing (Adobe Photoshop, Mountain View, Calif.). Subject 1 had 8 large polyps (2 to 5 cm) and about 33 small polyps (0.5 to 1 cm) in the descending and sigmoid colon. Subject 2 had 6 large polyps and about 17 small polyps in the cecum, ascending colon, and proximal transverse colon. The total number of colorectal polyps could not be ascertained. No "microadenomas" of the type seen in familial adenomatous polyposis were identified histopathologically in the colorectal mucosa of either subject. No affected member of the family was known to be living.

Molecular Genetic Analysis

The germ-line status of the APC gene, which is mutated in familial adenomatous polyposis, was determined in peripheral-blood-leukocyte DNA from at least one affected member of all 14 study families. The APC gene was analyzed by a ribonuclease (RNase) protection assay (reported previously for Families 2, 5, 6, 7, and 10),¹⁶ by an in vitro synthesized-protein assay,¹⁷ or by cloning and sequencing of the entire coding region of the APC gene.¹¹

The APC gene in the medulloblastoma of Patient 1B was analyzed with DNA from cryostat sections to minimize contamination by nonneoplastic cells.⁶⁰ We used an in vitro synthesized-protein assay in this analysis.¹⁷

Replication errors in DNA from brain and colorectal tumors were identified by the analysis of simple repeated genomic sequences (microsatellites) isolated from routine histopathological sections (Table 2).⁶¹ DNA from the surgical specimens of the subjects originally described with Turcot's syndrome¹ was unsatisfactory because the specimens had been fixed in Bouin's solution; only the slides of specimens obtained at autopsy from Subject 2 could be analyzed. Polymerase-chain-reaction (PCR) methods for the amplification of microsatellite sequences were used as described.^39,61 The minimal criterion for an error in replication was that at least one of the five markers tested contain a band in the tumor PCR product that was not found in the nonneoplastic PCR product. Because sporadic tumors positive for replication errors do occur,^{39,62,63,64,65} the finding of such an error in more than one tumor from a single patient was taken as evidence of a germ-line, rather than a somatic, mutation of a mismatch-repair gene.

View this table: [in this window] [in a new window]   Table 2. Molecular Genetic Characterization of Turcot's Syndrome.

 
The germ-line status of the hMSH2, hMLH1, hPMS1, and hPMS2 genes, which are found to be mutated in hereditary nonpolyposis colorectal cancer, was determined from RNA of peripheral-blood lymphocytes. An in vitro synthesized-protein assay and direct sequencing of the products of reverse transcription and PCR amplification were used as described.^33,34,37,38

Risk Analysis

To determine whether familial adenomatous polyposis predisposes patients to brain tumors, patients and their first-degree relatives enrolled in the Hopkins registry were compared with the general U.S. population, as represented in the surveillance, Epidemiology, and End Results (SEER) data.^26,29,30 None of the families in the registry were initially identified because of a proband who presented with a brain tumor. With a computer program for cohort analysis,⁶⁶ person-years at risk were calculated according to age-, race-, and sex-specific categories, from birth to 89 years of age, in subsequent five-year periods of observation to account for any trends over time. The expected numbers of brain tumors (classifications 1910 through 1919 of the International Classification of Diseases, 9th Revision [ICD-9]) and cerebellar medulloblastomas (ICD-9 classifications 1916 and M94703) were calculated by multiplying the number of patient-years by the corresponding incidence rates obtained from the SEER data.⁶⁷ The ratio of the number of observed cases to the expected number of cases was computed with a test of significance and a calculation of the 95 percent confidence intervals with the assumption of a Poisson distribution.

Results

Phenotypes of the Study Families

Twelve families met the clinical criteria for familial adenomatous polyposis⁵⁴ (Families 1 through 12 in Figure 1 and Table 1). In all but one family (Family 12), more than one member was affected. Extraintestinal lesions included those typical of familial adenomatous polyposis, but one patient (Patient 12) and his affected sister had café au lait spots, which are not associated with familial adenomatous polyposis but have been reported with Turcot's syndrome.³ Two families (Families 13 and 14) had colorectal adenomas and carcinoma without evidence of polyposis, and Family 14 met the criteria for hereditary nonpolyposis colorectal cancer.⁵⁵

Germ-Line Status of the APC Gene

We studied the APC gene in 14 families that included at least one affected member (Table 2). Among the 12 families classified as having polyposis, mutations were found in 10 (83 percent). All the mutated genes encoded truncated variants of the APC protein (Figure 2), as is true of the vast majority of patients with familial adenomatous polyposis.^15,17 The mutations were heterogeneous in type and location (Table 2), and there was no association between specific mutations and the development of brain tumors. Two families with polyposis (Families 5 and 12) and both families without polyposis (Families 13 and 14) had no identifiable germ-line APC mutations.

View larger version (16K): [in this window] [in a new window]   Figure 2. Germ-Line and Somatic Alterations in the APC Gene. In this example of analysis by an in vitro synthesized-protein assay,17 five overlapping segments encompassing the entire coding region of APC were amplified with specifically designed PCR primers that place the transcriptional and translational regulatory sequences at the 5' end of the PCR product. Radiolabeled protein was synthesized in vitro from these surrogate genes in a simple one-step coupled transcription–translation reaction. The truncating mutations could then be identified as smaller protein products after gel electrophoresis and autoradiography. The protein products from segment 2 (codons 686 to 1217) and segment 3 (codons 1099 to 1693) are shown. The lanes labeled L8 and L11 are from lymphoblastoid cell lines prepared from peripheral-blood lymphocytes of affected members of Families 8 and 11, respectively, whereas lane L1A is from the lymphoblastoid cell line of Patient 1A. The lane labeled M1B was prepared from the cryostat-dissected medulloblastoma of Patient 1B, the sister of Patient 1A. Truncated APC proteins are indicated by arrowheads. Affected members of Families 1 and 11 have germ-line mutations in segment 2 (arrowheads, lanes L1A and L11 of segment 2), whereas the affected member of Family 8 has a germ-line mutation in segment 3 (arrowhead, lane L8 of segment 3). The medulloblastoma from Patient 1B shows truncated protein (arrowhead, lane M1B) representing the same germ-line mutation as in her brother (arrowhead, lane L1A), but the brain tumor also lacks the full-length APC gene product (asterisk in lane M1B), indicating the somatic loss of the wild-type allele. Figure 1. Abbreviated Pedigrees of the 14 Families Included in the Study. Patients with brain tumors are indicated by arrows. When two members of the same family had verified brain tumors, as in Families 1, 3, 4, and 9, the patients are designated A and B. Solid quadrants indicate the presence of the findings indicated in the key. Open symbols without quadrant delineations indicate that the patient's clinical status is unknown, and numbers within symbols indicate the number of siblings of unknown clinical status. A hatched quadrant or parentheses around an arrow indicates a reported history unverified by medical records, and a dot in a quadrant indicates an uncertain history, as reported. Twelve families (Families 1 through 12) had the colorectal phenotype of adenomatous polyposis,54 whereas two families (Families 13 and 14) had colorectalcarcinoma with multiple adenomas but did not have the phenotype of polyposis.

 
Somatic Status of the APC Gene in a Brain Tumor

The medulloblastoma from Patient 1B, who had a germ-line mutation of the APC gene, was studied for a somatic mutation in the allele inherited from her unaffected parent. The in vitro synthesized-protein assay showed no wild-type APC gene product (Figure 2, lane M1B). This finding, which indicated that both copies of the gene had been inactivated, favored a direct role for the APC alterations in the pathogenesis of the brain tumor.

Phenotypic Characteristics of Patients with Germ-Line APC Mutations

In the 10 families with identified germ-line APC mutations, medulloblastoma predominated (in 11 patients, or 79 percent). Two patients had anaplastic astrocytomas, and one had an ependymoma. In 4 of the 10 families, two members had brain tumors. The clinical presentations of the patients varied. The brain tumor presented after the diagnosis of polyposis in four patients, but in six patients it was identified before polyposis was found. It is noteworthy that the brain tumors in Patients 3A and 3B in the same family were dramatically different: Patient 3A had an anaplastic astrocytoma at the age of 48, and Patient 3B had a medulloblastoma at the age of 6. The brain tumor was the cause of death in seven of the eight patients who died.

Risk Analysis for Brain Tumors

To determine whether familial adenomatous polyposis predisposes patients to brain tumors, we used risk analysis to compare families with familial adenomatous polyposis with the general population. Of the 1390 subjects in the Hopkins registry (with 18,673 patient-years of follow-up), there were 604 white male subjects, 645 white female subjects, 76 black male subjects, and 65 black female subjects. The registry revealed five brain tumors in patients with familial adenomatous polyposis and their at-risk relatives during the study period: three medulloblastomas (in Patients 1A, 3B, and 6), one glioblastoma multiforme (in Patient 5), and one ependymoma (in Patient 7). No brain tumors were found among the black subjects.

The relative risk of brain tumor (Table 3) was increased by a factor of 23 among the families with familial adenomatous polyposis in the group from birth to 29 years of age (P<0.001), and by a factor of 7 in the group as a whole (P<0.001). The corresponding relative risks of cerebellar medulloblastoma were 99 (P<0.001) and 92 (P<0.001), respectively. The absolute lifetime risk of brain tumor, however, was low: 1 in 3735 patient-years.

View this table: [in this window] [in a new window]   Table 3. Risk Analysis for Brain Tumors in Familial Adenomatous Polyposis.

 
Replication Errors in Brain and Colorectal Tumors

DNA replication errors characteristic of the abnormal mismatch repair in tumors of patients with hereditary nonpolyposis colorectal cancer were sought in 25 tumors from 10 patients with familial adenomatous polyposis and 5 affected relatives, representing nine families in the registry (Table 2 and Figure 3). In three patients the tumors had replication errors (Patients 12, 13, and 14), and in each there were at least two such tumors. Intertumoral heterogeneity of replication errors was found in two patients (Patients 13 and 14): they had colonic adenomas without replication errors, as well as colorectal tumors with such errors (an adenoma and four carcinomas). The microsatellite instability was less pronounced in the glioblastomas than in the colorectal neoplasms. None of the tumors from families with germ-line APC mutations had DNA replication errors.

View larger version (14K): [in this window] [in a new window]   Figure 3. Replication Errors in Brain and Colorectal Tumors (Upper Panels) and Germ-Line Mutations in Mismatch-Repair Genes (Lower Panels). Replication errors in tumors were identified by PCR amplification of repeated sequences on chromosome 18 (D18S58 and D18S55) or chromosome 2 (D2S123 and CA7). At the top, the lanes marked N show the results obtained after amplification of DNA isolated from nonneoplastic tissue. The lanes marked C represent colorectal tumors (a colorectal adenoma from Patient 12 and a colorectal carcinoma from Patient 14). The lanes marked B show PCR products from the brain tumors in these patients (glioblastoma multiforme in both). Shifted bands, indicating replication errors in the tumors, are indicated by arrowheads. The lower panels show the results of nucleotide-sequence analysis of the hPMS2 gene from Patient 12 and the hMLH1 gene from Patient 14. For Patient 12, the arrowhead indicates a C-to-T change (a new band in lane 2 of the T lanes and a less intense band in lane 2 of the C lanes) in codon 134 (CGA), which results in the creation of a premature termination codon (TGA). For Patient 14, the arrowhead indicates the first nucleotide of a three-nucleotide deletion that removes codon 618 (the deletion of AAG produces a downward shift by three positions for all bands in lane 1 above the arrowhead). In both cases, the sequence from the normal allele is also present, as expected.

 
Both the glioblastoma multiforme and a rectal adenoma from the autopsy of Subject 2 described by Turcot et al.¹ showed errors in DNA replication characteristic of hereditary nonpolyposis colorectal cancer.

Germ-Line Status of DNA Mismatch-Repair Genes

Analysis of the hMSH2, hMLH1, hPMS1, and hPMS2 mismatch-repair genes, which are mutated in hereditary nonpolyposis colorectal cancer, was carried out in the three patients with tumors that contained replication errors. Two had germ-line alterations: the hPMS2 gene was mutated in Patient 12, and hMLH1 was mutated in Patient 14 (Table 2 and Figure 3). No germ-line APC mutations were detected in these three patients.

Phenotypes of Patients with Brain and Colorectal Tumors Containing Replication Errors

The brain tumors in the three patients with tumors containing replication errors differed histopathologically from the brain tumors in patients with germ-line APC mutations. All three patients had glioblastoma multiforme, which was not found in any of the 10 families with identified APC gene mutations (P = 0.004). The glioblastoma presented before the colorectal neoplasms in two patients and afterward in one. The colorectal phenotypes and family histories of all three patients were atypical for familial adenomatous polyposis (Table 1). Patient 12 had café au lait spots.

One patient died of glioblastoma, but all three patients with DNA-replication errors had unusually long survival: Patient 13 lived for 36 months after diagnosis, and the other two remained alive 14 and 6 years after diagnosis. This long survival stands in contrast to the two-year survival rate of about 5 percent and the median survival of about eight months in the usual patients with glioblastoma multiforme.⁶⁸

Discussion

Our results indicate that the syndrome of primary brain tumors and multiple colorectal adenomas, which has previously been termed Turcot's syndrome, can be associated with two different types of germ-line genetic defects: mutation of the APC gene that is usually found in familial adenomatous polyposis, or mutation of a mismatch-repair gene that is usually found in hereditary nonpolyposis colorectal cancer. Moreover, we found molecular evidence of hereditary nonpolyposis colorectal cancer in the family originally described by Turcot and colleagues.

The phenotypes of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer have been regarded as distinctive, hence the descriptor "nonpolyposis" in hereditary nonpolyposis colorectal cancer. However, attenuated forms of familial adenomatous polyposis with small numbers of adenomas have been reported in families with mutations in the 5' portion of the APC gene.²⁰ Our findings also demonstrate the difficulty of distinguishing between these two genetically distinctive diseases on purely clinical grounds.³ Large numbers of colorectal adenomas, characteristic of familial adenomatous polyposis, occurred in two families that did not have the clinical criteria of hereditary nonpolyposis colorectal cancer (Family 12 and the family originally described by Turcot et al.). Nonetheless, in both families there was evidence of a germ-line mutation in a DNA mismatch-repair gene, which is characteristic of hereditary nonpolyposis colorectal cancer, rather than the APC mutation typical of familial adenomatous polyposis.

Thus, patients with Turcot's syndrome can be classified by testing for mutations of the APC gene and for mutant DNA mismatch-repair genes in peripheral-blood lymphocytes, and by evaluating tumor DNA for replication errors. The vast majority of cases should be definable by molecular genetics (13 of 14 families in our series; 95 percent confidence interval, 66 to 100 percent). This molecular approach will clarify the phenotypic spectrums of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer, which have been uncertain because of variations in the number and size of colonic adenomas.³ Our findings indicate that most patients with Turcot's syndrome who have small numbers of colorectal neoplasms, colorectal carcinoma in childhood or adolescence, glioblastoma, or café au lait spots^3,48,69 have hereditary nonpolyposis colorectal cancer rather than familial adenomatous polyposis.

This study sheds light on the mechanisms of tumorigenesis associated with the two different types of germ-line alterations. In patients with a germ-line mutation of APC, inactivation of the second copy of the gene appears to be a factor in brain tumorigenesis, as evidenced by Patient 1B. In a previous study, no mutation in the second copy of APC was found in the brain tumors of three patients with familial adenomatous polyposis,⁵² but this result could have been due to the technical difficulty of identifying alterations in the large APC gene. In addition, the markedly increased risk of brain tumor in our pedigrees with familial adenomatous polyposis (increased by a factor of 23 in the age range of birth to 29 years) is further strong evidence that the occurrence of brain tumors in familial adenomatous polyposis is not merely coincidental.⁷⁰ Thus, brain tumors, especially medulloblastoma, for which the relative risk was 92, represent a pleiotropic manifestation of the germ-line APC mutation. Specific germ-line APC mutations do not appear to be associated with the development of brain tumors, as evidenced by the striking heterogeneity of the APC mutations in our patients (Table 2).

Genetic characterization of the two inherited conditions has implications for patient care. Symptoms or signs suggesting central nervous system tumor require prompt and careful investigation in patients with familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or multiple tumors with replication errors, and in at-risk offspring or siblings. At-risk members of families with familial adenomatous polyposis who present with brain tumors can be tested for a mutant APC gene^17,18; they will require sigmoidoscopic surveillance for colorectal adenomas and colectomy if adenomas develop. We recommend vigilant neurologic evaluation of families with familial adenomatous polyposis in which a member has a brain tumor, because of familial clustering: 40 percent of the families we studied had two members with brain tumors.

Patients with brain tumors who have hereditary nonpolyposis colorectal cancer or multiple tumors with replication errors require a different type of care than do patients with familial adenomatous polyposis. Data supporting firm recommendations are incomplete. The relative and absolute risks of brain tumors in patients with germ-line mutations of the various mismatch-repair genes are unknown.⁴⁴ Routine genetic testing is not yet feasible. Nonetheless, complete colonoscopy, rather than sigmoidoscopy, should be used for surveillance, because of the predisposition to right-sided cancers in hereditary nonpolyposis colorectal cancer.⁴³ Surveillance of high-risk extracolonic sites in hereditary nonpolyposis colorectal cancer (i.e., the endometrium in women⁴⁴) may also be advisable.

The underlying germ-line genetic alteration may favorably influence the prognosis of patients with glioblastoma multiforme and colorectal neoplasia. Our series was too small to permit us to draw firm conclusions, but the length of survival of the four patients with glioblastoma was exceptional, with a minimum of three years until death. Long survival in similar cases has been reported.⁷¹ Improved stage-specific survival from colorectal cancer may be a feature of hereditary nonpolyposis colorectal cancer.⁴³ The extensive genomic alterations due to microsatellite instability may modify the behavior of various neoplasms and also elicit an improved host resistance and response.

Supported by the Clayton Fund and by grants (CA47527, CA45831, CA57345, CA35494, and CA62924) from the National Cancer Institute.

We are indebted to Dr. Mark Redston and Dr. Lawrence Seidenstein for assistance in obtaining pathological specimens, to Chris Kelley for assistance in data management, to Dr. Naomi Rance for reviewing some of the brain tumors, to Dr. John H. Yardley for reviewing the manuscript, and to Mrs. Nancy Folker for assistance in the preparation of the manuscript.

Source Information

From the Division of Gastrointestinal and Liver Pathology, Department of Pathology (S.R.H.); the Oncology Center (S.R.H., B.L., R.E.P., N.P., J.J., S.M.P., S.V.B., B.V., K.W.K.); the Division of Medical Genetics, Department of Medicine (A.J.K.); the Division of Neuropathology, Department of Pathology (P.C.B.); the Department of Pathology (F.T., G.J.A.O.); and the Division of Gastroenterology, Department of Medicine (F.M.G.); School of Medicine, and the Department of Epidemiology, the School of Hygiene and Public Health (G.M.P., A.C.T.), Johns Hopkins University, Baltimore; the Familial Gastrointestinal Cancer Registry, Mount Sinai Hospital, Toronto (T.B., Z.C.); the Laboratoire d'Anatomie Pathologique, Hôtel-Dieu de Québec, Quebec, Canada (B.T.); and the Division of Medical Oncology, Department of Medicine, Stratton Veterans Affairs Medical Center and Albany Medical College, Albany, N.Y. (P.A.W.).

Address reprint requests to Dr. Hamilton at the Department of Pathology, Ross Bldg., Rm. 632, Johns Hopkins University School of Medicine, 720 Rutland Ave., Baltimore, MD 21205-2196.

References

1. Turcot J, Després J-P, St Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 1959;2:465-468. [Medline]
2. Crail HW. Multiple primary malignancies arising in rectum, brain, and thyroid: report of a case. US Naval Med Bull 1949;49:123-8.
3. Itoh H, Hirata K, Ohsato K. Turcot's syndrome and familial adenomatous polyposis associated with brain tumor: review of related literature. Int J Colorectal Dis 1993;8:87-94. [CrossRef][Medline]
4. Jarvis L, Bathurst N, Mohan D, Beckly D. Turcot's syndrome: a review. Dis Colon Rectum 1988;31:907-914. [CrossRef][Medline]
5. McKusick VA. Genetic factors in intestinal polyposis. JAMA 1962;182:271-277. [Free Full Text]
6. Baughman FA Jr, List CF, Williams JR, Muldoon JP, Segarra JM, Volkel JS. the glioma-polyposis syndrome. N Engl J Med 1969;281:1345-1346.
7. Rustgi AK. Hereditary gastrointestinal polyposis and nonpolyposis syndromes. N Engl J Med 1994;331:1694-1702. [Free Full Text]
8. Lewis JH, Ginsberg AL, Toomey KE. Turcot's syndrome: evidence for autosomal dominant inheritance. Cancer 1983;51:524-528. [CrossRef][Medline]
9. Costa OL, Silva DM, Colnago FA, Vieira MS, Musso C. Turcot syndrome: autosomal dominant or recessive transmission? Dis Colon Rectum 1987;30:391-394. [CrossRef][Medline]
10. Kinzler KW, Nilbert MC, Su L-K, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-665. [Free Full Text]
11. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-669. [Free Full Text]
12. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600. [CrossRef][Medline]
13. Joslyn G, Carlson M, Thliveris A, et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991;66:601-613. [CrossRef][Medline]
14. Groden J, Gelbert L, Thliveris A, et al. Mutational analysis of patients with adenomatous polyposis: identical inactivating mutations in unrelated individuals. Am J Hum Genet 1993;52:263-272. [Medline]
15. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993;2:425-434. [CrossRef][Medline]
16. Miyoshi Y, Ando H, Nagase H, et al. Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci U S A 1992;89:4452-4456. [Free Full Text]
17. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993;329:1982-1987. [Free Full Text]
18. van der Luijt R, Khan PM, Vasen H, et al. Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. Genomics 1994;20:1-4. [CrossRef][Medline]
19. Bussey HJR. Familial polyposis coli: family studies, histopathology, differential diagnosis, and results of treatment. Baltimore: Johns Hopkins University Press, 1975:10.
20. Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993;75:951-957. [CrossRef][Medline]
21. Haggitt RC, Reid BJ. Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol 1986;10:871-887. [CrossRef][Medline]
22. Blair NP, Trempe CL. Hypertrophy of the retinal pigment epithelium associated with Gardner's syndrome. Am J Ophthalmol 1980;90:661-667. [Medline]
23. Traboulsi EI, Krush AJ, Gardner EJ, et al. Prevalence and importance of pigmented ocular fundus lesions in Gardner's syndrome. N Engl J Med 1987;316:661-667. [Abstract]
24. Giardiello FM, Offerhaus GJA, Traboulsi EI, et al. Value of combined phenotypic markers in identifying inheritance of familial adenomatous polyposis. Gut 1991;32:1170-1174. [Free Full Text]
25. Giardiello FM, Hamilton SR, Krush AJ, Offerhaus JA, Booker SV, Petersen GM. Nasopharyngeal angiofibroma in patients with familial adenomatous polyposis. Gastroenterology 1993;105:1550-1552. [Medline]
26. Offerhaus GJA, Giardiello FM, Krush AJ, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992;102:1980-1982. [Medline]
27. Gurbuz AK, Giardiello FM, Petersen GM, et al. Desmoid tumors in familial adenomatous polyposis. Gut 1994;35:377-381. [Free Full Text]
28. Kingston JE, Herbert A, Draper GJ, Mann JR. Association of hepatoblastoma and polyposis coli. Arch Dis Child 1983;58:959-962. [Free Full Text]
29. Giardiello FM, Offerhaus GJA, Krush AJ, et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr 1991;119:766-768. [CrossRef][Medline]
30. Giardiello FM, Offerhaus GJA, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993;34:1394-1396. [Free Full Text]
31. Peltomäki P, Aaltonen LA, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993;260:810-812. [Free Full Text]
32. Fishel R, Lescoe MK, Rao MRS, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-1038. [Erratum, Cell 1994;77:166a.] [CrossRef][Medline]
33. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-1225. [CrossRef][Medline]
34. Liu B, Parsons RE, Hamilton SR, et al. hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res 1994;54:4590-4594. [Free Full Text]
35. Lindblom A, Tannergard P, Werelius B, Nordenskjold M. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet 1993;5:279-282. [CrossRef][Medline]
36. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368:258-261. [CrossRef][Medline]
37. Papadopoulos N, Nicolaides NC, Wei Y-F, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625-1629. [Free Full Text]
38. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologs in hereditary nonpolyposis colon cancer. Nature 1994;371:75-80. [CrossRef][Medline]
39. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-816. [Free Full Text]
40. Parsons R, Li G-M, Longley MJ, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993;75:1227-1236. [CrossRef][Medline]
41. Lothe RA, Peltomäki P, Meling GI, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849-5852. [Free Full Text]
42. Aaltonen LA, Peltomäki P, Mecklin J-P, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994;54:1645-1648. [Free Full Text]
43. Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated view. Gastroenterology 1993;104:1535-1549. [Medline]
44. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71:677-685. [CrossRef][Medline]
45. Minami T, Himeno S, Shinomura Y, Kariya Y, Tarui S, Sakurai M. Rearrangement, amplification and overexpression of c-Ha Ras gene in premalignant lesion of Turcot's syndrome. Jpn J Med 1990;29:391-396. [Medline]
46. Newton HB, Rosenblum MK, Malkin MG. Turcot's syndrome: flow cytometric analysis. Cancer 1991;68:1633-1639. [CrossRef][Medline]
47. Rosenfeld M, Schlegel U, Malkin M, et al. p53 Mutations in glioma polyposis (Turcot syndrome). Neurology 1991;41:Suppl 1:304-304.abstract 
48. Tops CMJ, Vasen HFA, van Berge Henegouwen G, et al. Genetic evidence that Turcot syndrome is not allelic to familial adenomatous polyposis. Am J Med Genet 1992;43:888-893. [CrossRef][Medline]
49. Kikuchi T, Rempel SA, Rutz H-P, et al. Turcot's syndrome of glioma and polyposis occurs in the absence of germ line mutations of exons 5 to 9 of the p53 gene. Cancer Res 1993;53:957-961. [Free Full Text]
50. Rochlitz CF, Heide I, de Kant E, et al. Molecular alterations in a patient with Turcot's syndrome. Br J Cancer 1993;68:519-523. [Medline]
51. Paraf F. Syndrome de Turcot: évolution des connaissances. Gastroenterol Clin Biol 1994;18:297-299. [Medline]
52. Mori T, Nagase H, Horii A, et al. Germ-line and somatic mutations of the APC gene in patients with Turcot syndrome and analysis of APC mutations in brain tumors. Genes Chromosomes Cancer 1994;9:168-172. [Medline]
53. Lasser DM, DeVivo DC, Garvin J, Wilhelmsen KC. Turcot's syndrome: evidence for linkage to the adenomatous polyposis coli (APC) locus. Neurology 1994;44:1083-1086. [Free Full Text]
54. Bussey HJR. Familial polyposis coli: family studies, histopathology, differential diagnosis, and results of treatment. Baltimore: Johns Hopkins University Press, 1975:23.
55. Vasen HFA, Mecklin J-P, Khan PM, Lynch HT. Hereditary non-polyposis colorectal cancer. Lancet 1991;338:877-877. 
56. Cohen SB. Familial polyposis coli and its extracolonic manifestations. J Med Genet 1982;19:193-203. [Free Full Text]
57. Hamilton SR, Bussey HJR, Mendelsohn G, et al. Ileal adenomas after colectomy in nine patients with adenomatous polyposis coli/Gardner's syndrome. Gastroenterology 1979;77:1252-1257. [Medline]
58. Pierce ER, Weisbord T, McKusick VA. Gardner's syndrome: formal genetics and statistical analysis of a large Canadian kindred. Clin Genet 1970;1:65-80.
59. Tithecott GA, Filler R, Sherman PM. Turcot's syndrome: a diagnostic consideration in a child with primary adenocarcinoma of the colon. J Pediatr Surg 1989;24:1189-1191. [CrossRef][Medline]
60. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532. [Abstract]
61. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis of colorectal cancer. N Engl J Med 1994;331:213-221. [Free Full Text]
62. Peinado MA, Malkhosyan S, Velazquez A, Perucho M. Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci U S A 1992;89:10065-10069. [Free Full Text]
63. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-819. [Free Full Text]
64. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-561. [CrossRef][Medline]
65. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-156. [Abstract]
66. Coleman M, Douglas A, Hermon C, Peto J. Cohort study analysis with a Fortran computer program. Int J Epidemiol 1986;15:134-137. [Free Full Text]
67. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies. Lyon, France: International Agency for Research on Cancer, 1987. (IARC scientific publications no. 82.)
68. Black PM. Brain tumors. N Engl J Med 1991;324:1555-1564. [Medline]
69. Radin DR, Fortgang KC, Zee C-S, Mikity VG, Halls JM. Turcot syndrome: a case with spinal cord and colonic neoplasms. AJR Am J Roentgenol 1984;142:475-476. [Free Full Text]
70. Kropilak M, Jagelman DG, Fazio VW, Lavery IL, McGannon E. Brain tumors in familial adenomatous polyposis. Dis Colon Rectum 1989;32:778-782. [CrossRef][Medline]
71. Rutz HP, de Tribolet N, Calmes JM, Chapuis G. Long-time survival of a patient with glioblastoma and Turcot's syndrome. J Neurosurg 1991;74:813-815. [Medline]

Abstract PDF Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Related Letters:

The APC Gene in Turcot's Syndrome
Yong W. H., Raffel C., von Deimling A., Louis D. N., Rutz H. P., Kikuchi T.
Extract | Full Text  
N Engl J Med 1995; 333:524, Aug 24, 1995. Correspondence

Survival of Patients with Turcot's Syndrome and Glioblastoma
Merlo A., Rochlitz C., Scott R.
Extract | Full Text  
N Engl J Med 1996; 334:736-737, Mar 14, 1996. Correspondence

This article has been cited by other articles:

• Kyritsis, A. P., Bondy, M. L., Rao, J. S., Sioka, C. (2010). Inherited predisposition to glioma. Neuro Oncology 12: 104-113 [Abstract] [Full Text]  
• Hottinger, A. F., Khakoo, Y. (2009). Neurooncology of Familial Cancer Syndromes. J Child Neurol 24: 1526-1535 [Abstract]  
• Dhall, G. (2009). Medulloblastoma. J Child Neurol 24: 1418-1430 [Abstract]  
• Park, D. M., Yeaney, G. A., Hamilton, R. L., Mabold, J., Urban, N., Appleman, L., Flickinger, J., Lieberman, F., Mintz, A. (2009). Identifying Muir-Torre syndrome in a patient with glioblastoma multiforme. Neuro Oncology 11: 452-455 [Abstract] [Full Text]  
• Augustyn, A. M., Wallerstein, R. (2009). The Role of Pediatricians in Families with a History of Familial Adenomatous Polyposis. CLIN PEDIATR 48: 623-626 [Abstract]  
• Garre, M. L., Cama, A., Bagnasco, F., Morana, G., Giangaspero, F., Brisigotti, M., Gambini, C., Forni, M., Rossi, A., Haupt, R., Nozza, P., Barra, S., Piatelli, G., Viglizzo, G., Capra, V., Bruno, W., Pastorino, L., Massimino, M., Tumolo, M., Fidani, P., Dallorso, S., Schumacher, R. F., Milanaccio, C., Pietsch, T. (2009). Medulloblastoma Variants: Age-Dependent Occurrence and Relation to Gorlin Syndrome--A New Clinical Perspective. Clin. Cancer Res. 15: 2463-2471 [Abstract] [Full Text]  
• Uziel, T., Karginov, F. V., Xie, S., Parker, J. S., Wang, Y.-D., Gajjar, A., He, L., Ellison, D., Gilbertson, R. J., Hannon, G., Roussel, M. F. (2009). The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc. Natl. Acad. Sci. USA 106: 2812-2817 [Abstract] [Full Text]  
• Kongkham, P. N., Northcott, P. A., Ra, Y. S., Nakahara, Y., Mainprize, T. G., Croul, S. E., Smith, C. A., Taylor, M. D., Rutka, J. T. (2008). An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma. Cancer Res. 68: 9945-9953 [Abstract] [Full Text]  
• Marinovic-Terzic, I., Yoshioka-Yamashita, A., Shimodaira, H., Avdievich, E., Hunton, I. C., Kolodner, R. D., Edelmann, W., Wang, J. Y. J. (2008). Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q. Proc. Natl. Acad. Sci. USA 105: 13993-13998 [Abstract] [Full Text]  
• Feitsma, H., Kuiper, R. V., Korving, J., Nijman, I. J., Cuppen, E. (2008). Zebrafish with Mutations in Mismatch Repair Genes Develop Neurofibromas and Other Tumors. Cancer Res. 68: 5059-5066 [Abstract] [Full Text]  
• Fan, X., Eberhart, C. G. (2008). Medulloblastoma Stem Cells. JCO 26: 2821-2827 [Abstract] [Full Text]  
• Gururangan, S., Frankel, W., Broaddus, R., Clendenning, M., Senter, L., McDonald, M., Eastwood, J., Reardon, D., Vredenburgh, J., Quinn, J., Friedman, H. S. (2008). Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncology 10: 93-97 [Abstract] [Full Text]  
• Devlin, L. A, Morrison, P. J (2008). Inherited gynaecological cancer syndromes. The Obstetrician and Gynaecologist 10: 9-15 [Abstract] [Full Text]  
• Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., Weller, M., Schackert, G., for the German Glioma Network, (2007). Long-term survival with glioblastoma multiforme. Brain 130: 2596-2606 [Abstract] [Full Text]  
• Garcia-Donas, J., Rodriguez, N., Jara, C., Urioste, M., Nevado, M., Canamero, M., Cuartero, V., Albillos, J., Vega, D., Quintans, A. (2007). Retrorectal Cystic Hamartoma As Benign Cause of CA 19-9 Elevation. JCO 25: 4012-4014 [Full Text]  
• Lynch, H. T., Boland, C. R., Rodriguez-Bigas, M. A., Amos, C., Lynch, J. F., Lynch, P. M. (2007). Who Should Be Sent for Genetic Testing in Hereditary Colorectal Cancer Syndromes?. JCO 25: 3534-3542 [Abstract] [Full Text]  
• Rahman, N., Scott, R. H. (2007). Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 16: R60-R66 [Abstract] [Full Text]  
• Cahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., Iafrate, A. J., Louis, D. N. (2007). Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment. Clin. Cancer Res. 13: 2038-2045 [Abstract] [Full Text]  
• Lynch, H. T., Lynch, J. F., Lynch, P. M. (2007). Toward a Consensus in Molecular Diagnosis of Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome). JNCI J Natl Cancer Inst 99: 261-263 [Full Text]  
• Semmler, A., Simon, M., Moskau, S., Linnebank, M. (2006). The Methionine Synthase Polymorphism c.2756A>G Alters Susceptibility to Glioblastoma Multiforme.. Cancer Epidemiol. Biomarkers Prev. 15: 2314-2316 [Abstract] [Full Text]  
• Goecke, T., Schulmann, K., Engel, C., Holinski-Feder, E., Pagenstecher, C., Schackert, H. K., Kloor, M., Kunstmann, E., Vogelsang, H., Keller, G., Dietmaier, W., Mangold, E., Friedrichs, N., Propping, P., Kruger, S., Gebert, J., Schmiegel, W., Rueschoff, J., Loeffler, M., Moeslein, G. (2006). Genotype-Phenotype Comparison of German MLH1 and MSH2 Mutation Carriers Clinically Affected With Lynch Syndrome: A Report by the German HNPCC Consortium. JCO 24: 4285-4292 [Abstract] [Full Text]  
• Hendriks, Y. M.C., de Jong, A. E., Morreau, H., Tops, C. M.J., Vasen, H. F., Wijnen, J. Th., Breuning, M. H., Brocker-Vriends, A. H.J.T. (2006). Diagnostic Approach and Management of Lynch Syndrome (Hereditary Nonpolyposis Colorectal Carcinoma): A Guide for Clinicians. CA Cancer J Clin 56: 213-225 [Abstract] [Full Text]  
• Jaiswal, A. S., Balusu, R., Narayan, S. (2006). 7,12-Dimethylbenzanthracene-dependent transcriptional regulation of adenomatous polyposis coli (APC) gene expression in normal breast epithelial cells is mediated by GC-box binding protein Sp3. Carcinogenesis 27: 252-261 [Abstract] [Full Text]  
• Bonthron, D T, Hayward, B E, De Vos, M, Sheridan, E (2005). PMS2 mutations in childhood cancer. Gut 54: 1821-1821 [Full Text]  
• Gill, S., Lindor, N. M., Burgart, L. J., Smalley, R., Leontovich, O., French, A. J., Goldberg, R. M., Sargent, D. J., Jass, J. R., Hopper, J. L., Jenkins, M. A., Young, J., Barker, M. A., Walsh, M. D., Ruszkiewicz, A. R., Thibodeau, S. N. (2005). Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation. Clin. Cancer Res. 11: 6466-6471 [Abstract] [Full Text]  
• Durno, C, Aronson, M, Bapat, B, Cohen, Z, Gallinger, S (2005). Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut 54: 1146-1150 [Abstract] [Full Text]  
• Hegde, M. R., Chong, B., Blazo, M. E., Chin, L. H. E., Ward, P. A., Chintagumpala, M. M., Kim, J. Y., Plon, S. E., Richards, C. S. (2005). A Homozygous Mutation in MSH6 Causes Turcot Syndrome. Clin. Cancer Res. 11: 4689-4693 [Abstract] [Full Text]  
• Hui, A. B.Y., Takano, H., Lo, K.-W., Kuo, W.-L., Lam, C. N.Y., Tong, C. Y.K., Chang, Q., Gray, J. W., Ng, H.-K. (2005). Identification of a Novel Homozygous Deletion Region at 6q23.1 in Medulloblastomas Using High-Resolution Array Comparative Genomic Hybridization Analysis. Clin. Cancer Res. 11: 4707-4716 [Abstract] [Full Text]  
• Oliver, T. G., Read, T. A., Kessler, J. D., Mehmeti, A., Wells, J. F., Huynh, T. T. T., Lin, S. M., Wechsler-Reya, R. J. (2005). Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 132: 2425-2439 [Abstract] [Full Text]  
• Salahshor, S, Woodgett, J R (2005). The links between axin and carcinogenesis. J. Clin. Pathol. 58: 225-236 [Abstract] [Full Text]  
• Massimino, M., Gandola, L., Luksch, R., Spreafico, F., Riva, D., Solero, C., Giangaspero, F., Locatelli, F., Podda, M., Bozzi, F., Pignoli, E., Collini, P., Cefalo, G., Zecca, M., Casanova, M., Ferrari, A., Terenziani, M., Meazza, C., Polastri, D., Scaramuzza, D., Ravagnani, F., Fossati-Bellani, F. (2005). Sequential chemotherapy, high-dose thiotepa, circulating progenitor cellrescue, and radiotherapy for childhood high-grade glioma. Neuro Oncology 7: 41-48 [Abstract]  
• Bridge, R S Jr, Bridge, J A, Neff, J R, Naumann, S, Althof, P, Bruch, L A (2004). Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. J. Clin. Pathol. 57: 1172-1178 [Abstract] [Full Text]  
• Nakagawa, H., Lockman, J. C., Frankel, W. L., Hampel, H., Steenblock, K., Burgart, L. J., Thibodeau, S. N., de la Chapelle, A. (2004). Mismatch Repair Gene PMS2: Disease-Causing Germline Mutations Are Frequent in Patients Whose Tumors Stain Negative for PMS2 Protein, but Paralogous Genes Obscure Mutation Detection and Interpretation. Cancer Res. 64: 4721-4727 [Abstract] [Full Text]  
• Sivak-Sears, N. R., Schwartzbaum, J. A., Miike, R., Moghadassi, M., Wrensch, M. (2004). Case-Control Study of Use of Nonsteroidal Antiinflammatory Drugs and Glioblastoma Multiforme. Am J Epidemiol 159: 1131-1139 [Abstract] [Full Text]  
• Collins, V P (2004). Brain tumours: classification and genes. J. Neurol. Neurosurg. Psychiatry 75: ii2-ii11 [Full Text]  
• Hill, D. A., Inskip, P. D., Shapiro, W. R., Selker, R. G., Fine, H. A., Black, P. M., Linet, M. S. (2003). Cancer in First-Degree Relatives and Risk of Glioma in Adults. Cancer Epidemiol. Biomarkers Prev. 12: 1443-1448 [Abstract] [Full Text]  
• Siu, I-M., Lal, A., Blankenship, J. R., Aldosari, N., Riggins, G. J. (2003). c-Myc Promoter Activation in Medulloblastoma. Cancer Res. 63: 4773-4776 [Abstract] [Full Text]  
• Chung, D. C., Rustgi, A. K. (2003). The Hereditary Nonpolyposis Colorectal Cancer Syndrome: Genetics and Clinical Implications. ANN INTERN MED 138: 560-570 [Abstract] [Full Text]  
• Peltomaki, P. (2003). Role of DNA Mismatch Repair Defects in the Pathogenesis of Human Cancer. JCO 21: 1174-1179 [Abstract] [Full Text]  
• Shimodaira, H., Yoshioka-Yamashita, A., Kolodner, R. D., Wang, J. Y. J. (2003). Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc. Natl. Acad. Sci. USA 100: 2420-2425 [Abstract] [Full Text]  
• Parc, Y, Boisson, C, Thomas, G, Olschwang, S (2003). Cancer risk in 348 French MSH2 or MLH1 gene carriers. J. Med. Genet. 40: 208-213 [Full Text]  
• Wechsler-Reya, R. J. (2003). Analysis of Gene Expression in the Normal and Malignant Cerebellum. Recent Prog Horm Res 58: 227-248 [Abstract] [Full Text]  
• Tong, W.-M., Ohgaki, H., Huang, H., Granier, C., Kleihues, P., Wang, Z.-Q. (2003). Null Mutation of DNA Strand Break-Binding Molecule Poly(ADP-ribose) Polymerase Causes Medulloblastomas in p53-/- Mice. Am. J. Pathol. 162: 343-352 [Abstract] [Full Text]  
• Deng, F.-M., Liang, F.-X., Tu, L., Resing, K. A., Hu, P., Supino, M., Hu, C.-C. A., Zhou, G., Ding, M., Kreibich, G., Sun, T.-T. (2002). Uroplakin IIIb, a urothelial differentiation marker, dimerizes with uroplakin Ib as an early step of urothelial plaque assembly. JCB 159: 685-694 [Abstract] [Full Text]  
• Gould, T. D., Manji, H. K. (2002). The Wnt Signaling Pathway in Bipolar Disorder. Neuroscientist 8: 497-511 [Abstract]  
• Gonda, K., Nomizu, T., Fukayama, N., Sugano, K., Takenosita, S. (2002). A Novel Germline Mutation of hMLH1 in a Patient with Hereditary Non-polyposis Colorectal Cancer. Jpn J Clin Oncol 32: 215-218 [Abstract] [Full Text]  
• Palicio, M, Balmana, J, Gonzalez, S, Blanco, I, Marcuello, E, Peinado, M A, Julia, G, Germa, J R, Lopez Lopez, J J, Brunet, J, Capella, G (2002). Mismatch repair gene analysis in Catalonian families with colorectal cancer. J. Med. Genet. 39: e29-29 [Full Text]  
• Del Valle, L., Gordon, J., Enam, S., Delbue, S., Croul, S., Abraham, S., Radhakrishnan, S., Assimakopoulou, M., Katsetos, C. D., Khalili, K. (2002). Expression of Human Neurotropic Polyomavirus JCV Late Gene Product Agnoprotein in Human Medulloblastoma. JNCI J Natl Cancer Inst 94: 267-273 [Abstract] [Full Text]  
• Katballe, N, Christensen, M, Wikman, F P, Orntoft, T F, Laurberg, S (2002). Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients. Gut 50: 43-51 [Abstract] [Full Text]  
• Whiteside, D., McLeod, R., Graham, G., Steckley, J. L., Booth, K., Somerville, M. J., Andrew, S. E. (2002). A Homozygous Germ-Line Mutation in the Human MSH2 Gene Predisposes to Hematological Malignancy and Multiple Cafe-au-Lait Spots. Cancer Res. 62: 359-362 [Abstract] [Full Text]  
• Liu, T., Yan, H., Kuismanen, S., Percesepe, A., Bisgaard, M.-L., Pedroni, M., Benatti, P., Kinzler, K. W., Vogelstein, B., Ponz de Leon, M., Peltomaki, P., Lindblom, A. (2001). The Role of hPMS1 and hPMS2 in Predisposing to Colorectal Cancer. Cancer Res. 61: 7798-7802 [Abstract] [Full Text]  
• Dahmen, R. P., Koch, A., Denkhaus, D., Tonn, J. C., Sorensen, N., Berthold, F., Behrens, J., Birchmeier, W., Wiestler, O. D., Pietsch, T. (2001). Deletions of AXIN1, a Component of the WNT/wingless Pathway, in Sporadic Medulloblastomas. Cancer Res. 61: 7039-7043 [Abstract] [Full Text]  
• Grotzer, M. A., Hogarty, M. D., Janss, A. J., Liu, X., Zhao, H., Eggert, A., Sutton, L. N., Rorke, L. B., Brodeur, G. M., Phillips, P. C. (2001). MYC Messenger RNA Expression Predicts Survival Outcome in Childhood Primitive Neuroectodermal Tumor/Medulloblastoma. Clin. Cancer Res. 7: 2425-2433 [Abstract] [Full Text]  
• Fearnhead, N. S., Britton, M. P., Bodmer, W. F. (2001). The ABC of APC. Hum Mol Genet 10: 721-733 [Abstract] [Full Text]  
• Bale, A. E., Yu, K.-p. (2001). The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 10: 757-762 [Abstract] [Full Text]  
• STEIGERWALD, K., SANTORO, I. M, KORDICH, J. J, GISMONDI, V., TRZEPACZ, C., BADIALI, M., GIANGASPERO, F, BALKO, M G., GRAHAM, J. S, RATNER, N., LOWY, A. M, VARESCO, L., GRODEN, J. (2001). A distinct splice form of APC is highly expressed in neurones but not commonly mutated in neuroepithelial tumours. J. Med. Genet. 38: 257-262 [Full Text]  
• Alonso, M., Hamelin, R., Kim, M., Porwancher, K., Sung, T., Parhar, P., Miller, D. C., Newcomb, E. W. (2001). Microsatellite Instability Occurs in Distinct Subtypes of Pediatric but not Adult Central Nervous System Tumors. Cancer Res. 61: 2124-2128 [Abstract] [Full Text]  
• Abraham, S. C., Montgomery, E. A., Giardiello, F. M., Wu, T.-T. (2001). Frequent {beta}-Catenin Mutations in Juvenile Nasopharyngeal Angiofibromas. Am. J. Pathol. 158: 1073-1078 [Abstract] [Full Text]  
• Peel, D. J., Ziogas, A., Fox, E. A., Gildea, M., Laham, B., Clements, E., Kolodner, R. D., Anton-Culver, H. (2000). Characterization of Hereditary Nonpolyposis Colorectal Cancer Families From a Population-Based Series of Cases. JNCI J Natl Cancer Inst 92: 1517-1522 [Abstract] [Full Text]  
• Sobrido, M. J., Pereira, C. R., Barros, F., Forteza, J., Carracedo, A., Lema, M. (2000). Low frequency of replication errors in primary nervous system tumours. J. Neurol. Neurosurg. Psychiatry 69: 369-375 [Abstract] [Full Text]  
• Polakis, P. (2000). Wnt signaling and cancer. Genes Dev. 14: 1837-1851 [Full Text]  
• WHEELER, J M D, BODMER, W F, MORTENSEN, N J M. (2000). DNA mismatch repair genes and colorectal cancer. Gut 47: 148-153 [Full Text]  
• Goss, K. H., Groden, J. (2000). Biology of the Adenomatous Polyposis Coli Tumor Suppressor. JCO 18: 1967-1979 [Abstract] [Full Text]  
• Huang, H., Mahler-Araujo, B. M., Sankila, A., Chimelli, L., Yonekawa, Y., Kleihues, P., Ohgaki, H. (2000). APC Mutations in Sporadic Medulloblastomas. Am. J. Pathol. 156: 433-437 [Abstract] [Full Text]  
• Syngal, S., Fox, E. A., Li, C., Dovidio, M., Eng, C., Kolodner, R. D., Garber, J. E. (1999). Interpretation of Genetic Test Results for Hereditary Nonpolyposis Colorectal Cancer: Implications for Clinical Predisposition Testing. JAMA 282: 247-253 [Abstract] [Full Text]  
• Adesma, A. M. (1999). Topical Review: Molecular Heterogeneity in Medulloblastoma With Implications for Differing Tumor Biology. J Child Neurol 14: 411-417 [Abstract]  
• Weber, T. K., Chin, H.-M., Rodriguez-Bigas, M., Keitz, B., Gilligan, R., O'Malley, L., Urf, E., Diba, N., Pazik, J., Petrelli, N. J. (1999). Novel hMLH1 and hMSH2 Germline Mutations in African Americans With Colorectal Cancer. JAMA 281: 2316-2320 [Abstract] [Full Text]  
• Potter, J. D. (1999). Colorectal Cancer: Molecules and Populations. JNCI J Natl Cancer Inst 91: 916-932 [Abstract] [Full Text]  
• Bogardus, S. T. Jr, Concato, J., Feinstein, A. R. (1999). Clinical Epidemiological Quality in Molecular Genetic Research: The Need for Methodological Standards. JAMA 281: 1919-1926 [Abstract] [Full Text]  
• Hurko, O., Provost, T. T (1999). Neurology and the skin. J. Neurol. Neurosurg. Psychiatry 66: 417-430 [Full Text]  
• Biegel, J. A. (1999). Cytogenetics and molecular genetics of childhood brain tumors. Neuro Oncology 1: 139-151 [Abstract]  
• Kim, J. Y. H., Sutton, M. E., Lu, D. J., Cho, T. A., Goumnerova, L. C., Goritchenko, L., Kaufman, J. R., Lam, K. K., Billet, A. L., Tarbell, N. J., Wu, J., Allen, J. C., Stiles, C. D., Segal, R. A., Pomeroy, S. L. (1999). Activation of Neurotrophin-3 Receptor TrkC Induces Apoptosis in Medulloblastomas. Cancer Res. 59: 711-719 [Abstract] [Full Text]  
• Leung, S. Y., Chan, T. L., Chung, L. P., Chan, A. S. Y., Fan, Y. W., Hung, K. N., Kwong, W. K., Ho, J. W. C., Yuen, S. T. (1998). Microsatellite Instability and Mutation of DNA Mismatch Repair Genes in Gliomas. Am. J. Pathol. 153: 1181-1188 [Abstract] [Full Text]  
• Nicolaides, N. C., Littman, S. J., Modrich, P., Kinzler, K. W., Vogelstein, B. (1998). A Naturally Occurring hPMS2 Mutation Can Confer a Dominant Negative Mutator Phenotype. Mol. Cell. Biol. 18: 1635-1641 [Abstract] [Full Text]  
• Narayan, S., Jaiswal, A. S. (1997). Activation of Adenomatous Polyposis Coli (APC) Gene Expression by the DNA-alkylating Agent N-MethylN'-nitro-N-nitrosoguanidine Requires p53. J. Biol. Chem. 272: 30619-30622 [Abstract] [Full Text]  
• Giardiello, F. M. (1997). Genetic Testing in Hereditary Colorectal Cancer. JAMA 278: 1278-1281 [Abstract]  
• Narayanan, L., Fritzell, J. A., Baker, S. M., Liskay, R. M., Glazer, P. M. (1997). Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2. Proc. Natl. Acad. Sci. USA 94: 3122-3127 [Abstract] [Full Text]  
• Merlo, A., Rochlitz, C., Scott, R. (1996). Survival of Patients with Turcot's Syndrome and Glioblastoma. NEJM 334: 736-737 [Full Text]  
• Yong, W. H., Raffel, C., von Deimling, A., Louis, D. N., Rutz, H. P., Kikuchi, T. (1995). The APC Gene in Turcot's Syndrome. NEJM 333: 524-524 [Full Text]  
• Samowitz, W. S., Burt, R. W., Leppert, M., Dupuis, M.J.M., Verellen-Dumoulin, C., Coyle, T., Ellis, M. F., Whitelaw, S., Rustgi, A. K. (1995). Gastrointestinal Polyposis and Nonpolyposis Syndromes. NEJM 332: 1518-1520 [Full Text]  
• Parsons, R, Li, G., Longley, M, Modrich, P, Liu, B, Berk, T, Hamilton, SR, Kinzler, K., Vogelstein, B (1995). Mismatch repair deficiency in phenotypically normal human cells. Science 268: 738-740 [Abstract]  
• Groden, J. (1995). Colon-Cancer Genes and Brain Tumors. NEJM 332: 884-885 [Full Text]  
• Jaiswal, A. S., Narayan, S. (2001). p53-dependent Transcriptional Regulation of the APC Promoter in Colon Cancer Cells Treated with DNA Alkylating Agents. J. Biol. Chem. 276: 18193-18199 [Abstract] [Full Text]